Literature DB >> 24989017

Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.

Lisbeth Aranbicia Aguila1, Michelle Remião Ugolini Lopes, Flavia Zon Pretti, Percival Degrava Sampaio-Barros, Fernando Henrique Carlos de Souza, Eduardo Ferreira Borba, Samuel Katsuyuki Shinjo.   

Abstract

Because overlap syndromes (OSs) are rarely described, we analyzed retrospectively their frequencies and correlations in Brazilian series of 31 patients with dermatomyositis (DM)/polymyositis (PM) associated with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or rheumatoid arthritis (RA) attended at a referral single center. Myositis-specific autoantibodies (MSAs: anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-SRP, anti-Mi-2) and myositis-associated autoantibodies (MAAs: anti-PM-Scl75, anti-PM-Scl100, anti-Ku) as well as specific autoantibodies related to SLE, SSc, and RA were investigated. The mean age of the OS patients (9 DM and 22 PM) was 44.6 ± 15.4 years, with a predominance of women (83.9 %) and white ethnicity (58.1 %). PM was the most frequent inflammatory myopathy, and the clinical presentation of DM/PM was significantly different among the OS groups. Overlap was found with SSc (48.4 %), SLE (29.0 %), and RA (22.6 %). The clinical manifestations of DM/PM were identified simultaneously with SSc and RA in the majority of cases, in contrast to identification in the SLE group (p < 0.05). All patients were positive for antinuclear antibodies, and the prevalence of MSA and MAA was 38.8 % in all OS groups, mutually exclusive, and more frequent in the SSc group. Comparing the clinical and laboratory features, there was a higher frequency of vascular (skin ulcers, Raynaud's phenomenon) and pulmonary (interstitial lung disease) involvement in the SSc group (p < 0.05). Moreover, there were no differences among the groups in relation to disease relapse and deaths. Concluding, this is the first study to show the different characteristics of a series of patients with connective tissue disease (CTD)-OS in the heterogeneous Brazilian population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989017     DOI: 10.1007/s10067-014-2730-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

3.  Calcinosis universalis in a patient with overlap of scleroderma/dermatomyositis.

Authors:  Saeedeh Shenavandeh
Journal:  J Clin Rheumatol       Date:  2012-01       Impact factor: 3.517

4.  A case of overlap syndrome of systemic sclerosis and dermatomyositis with right ventricular dysplasia.

Authors:  M Imakita; C Yutani; H Ishibashi-Ueda; K Miyatake
Journal:  Hum Pathol       Date:  1991-05       Impact factor: 3.466

5.  Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients.

Authors:  Andrea Váncsa; Lajos Gergely; Andrea Ponyi; Gabriella Lakos; Júlia Németh; Péter Szodoray; Katalin Dankó
Journal:  Joint Bone Spine       Date:  2010-02-25       Impact factor: 4.929

6.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

7.  A juvenile case of overlap syndrome of systemic lupus erythematosus and polymyositis, later accompanied by systemic sclerosis with the development of anti-Scl 70 and anti-Ku antibodies.

Authors:  Y Nitta; M Muramatsu
Journal:  Pediatr Dermatol       Date:  2000 Sep-Oct       Impact factor: 1.588

8.  Childhood sclerodermatomyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands.

Authors:  V García-Patos; R Bartralot; V Fonollosa; C Arnal; M Boronat; C Gelpí; J L Rodríguez; A Castells
Journal:  Br J Dermatol       Date:  1996-10       Impact factor: 9.302

Review 9.  Overlap connective tissue disease syndromes.

Authors:  Luca Iaccarino; Mariele Gatto; Silvano Bettio; Francesco Caso; Mariaelisa Rampudda; Margherita Zen; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Autoimmun Rev       Date:  2012-06-26       Impact factor: 9.754

10.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

View more
  19 in total

Review 1.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort.

Authors:  R Naveen; Upendra Rathore; Vikas Agarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-01-10       Impact factor: 2.631

Review 3.  Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.

Authors:  Sarah L Tansley; Neil J McHugh
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 4.  Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.

Authors:  Jucier Gonçalves Júnior; Naoki Mugii; Pleiades Tiharu Inaoka; Percival Degrava Sampaio-Barros; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2022-02-27       Impact factor: 2.980

5.  [Clinical and immunological characteristics of 88 cases of overlap myositis].

Authors:  Y S Xiao; F Y Zhu; L Luo; X Y Xing; Y H Li; X W Zhang; D H Shen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

Review 6.  Antisynthetase syndrome: A distinct disease spectrum.

Authors:  Kun Huang; Rohit Aggarwal
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

7.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

8.  Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.

Authors:  Rebecca De Lorenzo; Iago Pinal-Fernandez; Wilson Huang; Jemima Albayda; Eleni Tiniakou; Cheilonda Johnson; Jose C Milisenda; Maria Casal-Dominguez; Andrea M Corse; Sonye K Danoff; Lisa Christopher-Stine; Julie J Paik; Andrew L Mammen
Journal:  Neurology       Date:  2018-05-04       Impact factor: 9.910

9.  Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies.

Authors:  Adam Maundrell; Susanna Proudman; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-08-05       Impact factor: 2.631

10.  The spectrum of idiopathic inflammatory myopathies in South Africa.

Authors:  Keith J Chinniah; Girish M Mody
Journal:  Clin Rheumatol       Date:  2020-03-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.